{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032781","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.580869+00:00","generated_at":"2026-06-10T16:21:26.540486+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evofem shareholders approve increase in authorized common shares to 3 billion","bullets":["Authorized common shares increased to 3,000,000,000 (from previous amount) effective Sept 15, 2023.","Saundra Pelletier re-elected as Class III director; advisory say-on-pay approved with 4.75M votes for.","BPM LLP ratified as independent auditor for FY 2023; all proposals passed with large majorities.","Meeting quorum: 5,011,486 votes (58.6% of eligible) with common stock holders representing 13%.","Massive authorized share increase signals potential substantial dilution for existing shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032781","json":"https://secwatch.observer/filing/0001493152-23-032781.json","markdown":"https://secwatch.observer/filing/0001493152-23-032781.md","text":"https://secwatch.observer/filing/0001493152-23-032781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T16:21:26.540486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"505313355251a8bba58997508fc79df62d05a23b","claim":"Evofem Biosciences, Inc.: Increased total authorized common shares to 3,000,000,000 (effective 2023-09-15).","evidence_excerpt":"the Company’s stockholders approved a resolution to amend the Company’s existing Amended and Restated Certificate of Incorporation (“Certificate”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-15"}],"fact_type":"governance_change"},{"claim_id":"2f53e9767193e4d885dfd0577b834a4898db4303","claim":"Evofem Biosciences, Inc. shareholders approved Ratification of the appointment of BPM LLP as the Company's Independent Registered Public Accounting firm for the year ending December 31, 2023 at the 2023-09-14 meeting.","evidence_excerpt":"Proposal 4 Ratification of the appointment of BPM LLP as the Company’s Independent Registered Public Accounting firm for the year ending December 31, 2023. Votes For Votes Against Votes Withheld Broker Non-Vote 4,943,298 34,100 34,088 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-14"}],"fact_type":"shareholder_vote"},{"claim_id":"6c036177af628a32c0e2fce2f2161c9031bbf734","claim":"Evofem Biosciences, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of our named executive officers at the 2023-09-14 meeting.","evidence_excerpt":"Proposal 2 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. Votes For Votes Against Votes Withheld Broker Non-Vote 4,754,413 185,842 71,231 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-14"}],"fact_type":"shareholder_vote"},{"claim_id":"c7ac0bba9b5fb47ee85d48159c04c780b213a6e0","claim":"Evofem Biosciences, Inc. shareholders approved Election of Saundra Pelletier as a Class III director at the 2023-09-14 meeting.","evidence_excerpt":"Proposal 1 Election of the following nominee as a Class III director of the company, to serve a three-year term until the 2026 Annual Meeting of Stockholders and until her successor is duly elected and qualified. Votes For Votes Against Votes Withheld Broker Non-Vote Saundra Pelletier 4,821,109 - 190,377 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-14"}],"fact_type":"shareholder_vote"},{"claim_id":"d9a4536d3ab557e8d2f36858a3052cb9f0976a8f","claim":"Evofem Biosciences, Inc. shareholders approved Approval of the amendment to the Company's Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000 at the 2023-09-14 meeting.","evidence_excerpt":"Proposal 3 Approval of the amendment unanimously approved by the Company’s board of directors to the Company’s Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000. Votes For Votes Against Votes Withheld Broker Non-Vote 4,722,280 271,079 18,127 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}